Drug Trial Radar · NCT06701721
A Study Intravitreal THN391 in Diabetic Macular Oedema Secondary to Non-Proliferative Diabetic Retinopathy.
Last checked: Nov 20, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
21
Planned (sponsor's estimate)
Start
Dec 20, 2024
Primary completion
Mar 31, 2027
Study completion May 31, 2027
Sponsor
- Lead sponsor
- Therini Bio Pty LtdIndustry
- Sponsor type
- Industry
- Collaborators
- Therini Bio, Inc.
- First posted
- Nov 22, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
THN391-OPT-101 is a study assessing safety and preliminary efficacy of THN391 in patients with diabetic macular edema (DME) given as monotherapy.
Conditions
- Diabetic Macular Edema
- Diabetic Retinopathy
Interventions
THN391Drug
THN391, IVT injection, 3\*Q4W (every 4 weeks)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse EventsTime frame: Up to 16 weeks following first dose administration
Locations
10 sites in 2 countries. Site status is shown where the registry gives one.
Marsden Eye Specialists
Parramatta, New South Wales, Australia · Recruiting
South Eastern Sydney Local Health District
Sydney, New South Wales, Australia · Recruiting
Sydney West Retina
Westmead, New South Wales, Australia · Terminated
Princess Alexandria Hospital
Woolloongabba, Queensland, Australia · Terminated
Royal Adelaide Hospital
Adelaide, South Australia, Australia · Recruiting
Sunshine Eye Surgeons
Albans, Victoria, Australia · Recruiting
Eye Surgery Associates Pty Ltd
Malvern, Victoria, Australia · Recruiting
Ltd Akhali Mzera
Tbilisi, Georgia · Recruiting
LLC Caucasus Medical Center
Tbilisi, Georgia · Recruiting
Davinci
Tbilisi, Georgia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.